Clinical Trials · NCT06517212
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Baylor Research Institute
- Enrollment
- 48
- Start date
- Nov 2024
- Locations
- 1 site, United States
- Primary endpoint
- ctDNA efficacy